|
|
Blood, 15 December 2003, Vol. 102, No. 13, pp. 4472-4478.
Prepublished online as a Blood First Edition Paper on August 28, 2003; DOI 10.1182/blood-2002-11-3624.
 Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
Differential requirement for A2a and A3 adenosine receptors for the protective effect of inosine in vivo
Gregorio Gomez, and
Michail V. Sitkovsky
From the Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Inosine is an endogenous nucleoside with immunosuppressive properties that is known to inhibit the accumulation of proinflammatory cytokines and protect mice from endotoxin-induced inflammation and lung tissue damage. There are no known receptors specific for inosine, but A3 adenosine receptors (A3Rs) have been shown to bind inosine, resulting in mast cell degranulation and increased vascular permeability. The present study specifically addresses the requirement for A2aR and/or A3R for the protective effect of inosine in 2 experimental in vivo models of inflammatory disease. The data show that A3R is essential for protection against ConA-induced fulminant hepatitis since only A3R-expressing mice were protected by inosine whereas wild-type and A2aR-deficient mice exhibited severe liver damage even after administration of inosine. In addition, we show in a model of LPS-induced endotoxemia that inosine protected both A2aR-/- and A3R-/- mice from inflammation, but not A2aA3R double-null mice, indicating that in this model both A2aR and A3R were used by inosine. Thus, we demonstrate that A2a and A3 adenosine receptors are differentially utilized by inosine for the down-regulation of tissue damage under different inflammatory conditions in vivo. (Blood. 2003;102:4472-4478)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Ryzhov, R. Zaynagetdinov, A. E. Goldstein, S. V. Novitskiy, M. R. Blackburn, I. Biaggioni, and I. Feoktistov
Effect of A2B Adenosine Receptor Gene Ablation on Adenosine-Dependent Regulation of Proinflammatory Cytokines
J. Pharmacol. Exp. Ther.,
February 1, 2008;
324(2):
694 - 700.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Kobie, P. R. Shah, L. Yang, J. A. Rebhahn, D. J. Fowell, and T. R. Mosmann
T Regulatory and Primed Uncommitted CD4 T Cells Express CD73, Which Suppresses Effector CD4 T Cells by Converting 5'-Adenosine Monophosphate to Adenosine
J. Immunol.,
November 15, 2006;
177(10):
6780 - 6786.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Levy, M. Coughlin, B. N. Cronstein, R. M. Roy, A. Desai, and M. R. Wessels
The Adenosine System Selectively Inhibits TLR-Mediated TNF-{alpha} Production in the Human Newborn
J. Immunol.,
August 1, 2006;
177(3):
1956 - 1966.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Guinzberg, D. Cortes, A. Diaz-Cruz, H. Riveros-Rosas, R. Villalobos-Molina, and E. Pina
Inosine released after hypoxia activates hepatic glucose liberation through A3 adenosine receptors
Am J Physiol Endocrinol Metab,
May 1, 2006;
290(5):
E940 - E951.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Fortin, D. Harbour, M. Fernandes, P. Borgeat, and S. Bourgoin
Differential expression of adenosine receptors in human neutrophils: up-regulation by specific Th1 cytokines and lipopolysaccharide
J. Leukoc. Biol.,
March 1, 2006;
79(3):
574 - 585.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Shen, G.-J. Chen, B. K. Harvey, P. C. Bickford, and Y. Wang
Inosine Reduces Ischemic Brain Injury in Rats
Stroke,
March 1, 2005;
36(3):
654 - 659.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Buckley, L. Barsky, K. Weinberg, and D. Warburton
In vivo inosine protects alveolar epithelial type 2 cells against hyperoxia-induced DNA damage through MAP kinase signaling
Am J Physiol Lung Cell Mol Physiol,
March 1, 2005;
288(3):
L569 - L575.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
